Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this case study, a 29-year-old man with alopecia areata experienced satisfactory hair regrowth after five months of combined intralesional triamcinolone acetonide and platelet-rich plasma therapy.

Inositol helped cure hair loss around rats' eyes and improved their growth.

This phase 3 trial found that over 50% of adolescents with severe alopecia areata achieved successful hair regrowth after 52 weeks on baricitinib 4-mg, with no new safety concerns reported compared to existing safety profiles.

The study suggests that refractory chronic alopecia areata cases have more infiltrating skin resident memory T cells, and using a JAK inhibitor may be an effective treatment option.

This report documented a case of thrombocytopenia and leukopenia linked to the long-term use of itraconazole in a patient with acute myelogenous leukemia.

This study reports a strong association between the MICA locus, specifically the MICA∗3-DR∗6-DQ6 haplotype, and Alopecia Areata in families.

CD8+ T cells re-expressing CD45RA may predict treatment resistance in severe alopecia areata.

In a retrospective clinical study, this research found that baricitinib is effective for alopecia areata, with 42.3% of patients achieving a significant reduction in hair loss by week 36, and 52.4% by week 52, outperforming previous trials.

This study found that in a mouse model of Ross River virus-induced joint inflammation, targeting IL-17A and IL-17A/F heterodimers reduced disease severity.

In this study, intralesional triamcinolone acetonide injections were associated with halting the progression of frontal fibrosing alopecia in female patients and showed minimal adverse effects, but the efficacy as sole therapy remains unclear pending further trials.

This study demonstrated that mice lacking skin-specific RXRalpha expression developed hair follicle degeneration and alopecia, indicating the importance of RXRalpha/VDR heterodimers in maintaining hair follicle homeostasis.

In this case report, researchers observed that a 35-year-old male with alopecia universalis achieved full regrowth of scalp, eyebrow, and facial hair with oral upadacitinib treatment after previous therapies failed to provide lasting relief.

This case study observed isoniazid-induced alopecia in a patient, which was confirmed as reversible since hair regrowth resumed after the drug was discontinued.

In these randomized, placebo-controlled trials, patients with alopecia areata who received baricitinib showed significantly higher eyebrow and eyelash hair regrowth rates compared to placebo, with greater responses observed at the 4 mg dose and in those achieving overall scalp hair improvement by Week 52.

This case report describes the treatment of a 12-year-old female with Alopecia Areata using oral azathioprine.

This study found that patients with rheumatoid arthritis taking tofacitinib had higher rates of serious adverse events compared to those with alopecia areata, highlighting the need for careful assessment when using it off-label for alopecia areata.

This study found that upadacitinib significantly improved hair regrowth compared to placebo in adults and adolescents with severe alopecia areata, and demonstrated a positive benefit-risk profile.

This study shows that IKZF1 and the protein IKAROS may play a role in the development of alopecia areata, based on findings from both mouse models and human scalp tissues.

QIA-64 software can measure straight wire lengths accurately but needs improvement for curved wires and width measurements.

This study found that ionizing irradiation significantly inhibits proliferation and induces apoptosis in human hair follicle keratinocytes, suggesting its potential as a preclinical assay system for testing radioprotectants.

This study introduces a novel image enhancement method that significantly improves the visual quality of low-light sports images by utilizing improved bilateral filtering and the CLAHE algorithm, achieving a 65.24% improvement in color and edge detail preservation compared to state-of-the-art methods on the LOL dataset.

Baricitinib helps regrow hair in severe alopecia areata and is safe, but more research is needed.

This study identified specific reflectance confocal microscopy features that help differentiate scarring from non-scarring alopecia, providing a non-invasive diagnostic tool.

Ritlecitinib may help young adults with severe alopecia areata when ketoconazole doesn't work.

Baricitinib helps keep hair, eyebrows, and eyelashes regrown for 3 years in most people with severe hair loss.

In this study, the KPAI and KP-IGA scoring systems for assessing keratosis pilaris showed excellent interrater and intrarater reliability, offering standardized measures for clinical and research use.

This announcement explains the Fellow designation for hair restoration surgeons meeting specific educational criteria, without reporting new research findings.

This study found that escalating baricitinib to 6 mg daily improved hair loss in 75% of patients with severe refractory alopecia areata who responded poorly to standard treatments, while also noting manageable short-term safety concerns under close monitoring.

In a mouse model, this study reported that the compound isoalantolactone significantly improved hair growth and thickness, suggesting its potential as a treatment for hair loss.

This study suggests that rather than inhibiting IL-15, selectively stimulating IL-15Ra-mediated signaling could be beneficial for managing alopecia areata and possibly other inflammatory hair loss conditions, as IL-15 promoted hair growth and maintained immune privilege in human hair follicles.